OncoMatch/Clinical Trials/NCT05227326
AOH1996 for the Treatment of Refractory Solid Tumors
Is NCT05227326 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies PCNA Inhibitor AOH1996 for refractory malignant solid neoplasm.
Treatment: PCNA Inhibitor AOH1996 — This phase I trial studies the side effects and best dose of AOH1996 in treating patients with solid tumors that do not respond to treatment (refractory). AOH1996 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Check if I qualifyExtracted eligibility criteria
Cancer type
Tumor Agnostic
Osteosarcoma
Ovarian Cancer
Non-Small Cell Lung Carcinoma
Pancreatic Cancer
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Lab requirements
Blood counts
anc ≥ 1,500/mm3; platelets ≥ 100,000/mm3
Kidney function
creatinine clearance of ≥ 60 ml/min per 24 hour urine or the cockcroft-gault
Liver function
total serum bilirubin ≤ 1.5 x uln; ast ≤ 1.5 x uln or ≤ 3 x uln with liver metastases; alt ≤ 1.5 x uln or ≤ 3 x uln with liver metastases
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Honor Health Research and Innovation Institute · Scottsdale, Arizona
- City of Hope Medical Center · Duarte, California
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify